Should aTTR mutation with bilateral carpal tunnel alone prompt treatment with a gene silencing drug?

Carpal tunnel syndrome does not qualify as a peripheral neuropathy due to TTR amyloid. The amyloid deposition is in the soft and/or connective tissue and not in the nerve. As such, there is no clear indication to treat as much as one might be tempted. Careful follow-up and treatment as soon as neuro...

FDA coverage of the drug for TTR requires peripheral neuropathy and some form of tissue diagnosis, or at least evidence suggesting such as PyP, MRI spec, or biopsy. Even with peripheral neuropathy, often the aim for insurance coverage is stage 2B using the diabetic peripheral neuropathy scoring syst...